Validating AIM-Based Instrumentation and Associated Measurement Techniques - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 301

Table 10.9 Experiment order in the AstraZeneca (UK) 2011 FPD-AVCI evaluation study

pMDI actuation
numbers Experiment pMDI no. Impactor

6-Stage ACI (control) 1 1-6 A

2 B

3 C

sACI with Brij-coated plates 1 9-11 A

2 C

3 B

FPD-AVCI with Brij-coated petri dishes 1 14-16 A

2 B

3 C

FPD-AVCI with Brij-coated filter on petri dishes 1 19-21 B

2 A

3 C

sACI with Brij-coated filter on plates 1 24-26 C

2 A

3 B

Fig. 10.22 Impactor mass ( IM ) of API expressed as % of nominal dose recovered from the various
systems evaluated by Chambers et al . ( From [ 32 ]— used with permission )

following the practice described in Sect. 10.4 for the second stage of the AIM-pHRT
system evaluated at TMI [ 27 ]. Three impactors of each type were evaluated, but in
order to guard against systematic bias in the different experiments, the impactor
order was swapped between experiments (Table 10.9 ). The measurement of IM as
percentage of the nominal dose by sACI with Brij-coated Petri dishes was in closest
agreement with that obtained from the control ACI (Fig. 10.22 ).